PharmaCyte Biotech, Inc. stock is down -2.67% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 20 February’s closed higher than January.
PharmaCyte Biotech, Inc. focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!